Loading
Jaguar Health, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wolin Jonathan S., was filed 03 Jan 2023.
Jaguar Health, Inc.: what insiders have been doing
Jaguar Health, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 9 filings came from 9 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
There has been no open-market purchase by an insider of Jaguar Health, Inc. for at least a year. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 9 filings here. Since 2016, the database holds 13 purchases and 3 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 11.5 m USD and net income at -53.6 m USD.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
77
Thresholds
n/a
Buy Volume
€813,806
13 ops. · all time
Sell Volume
€507,199
3 ops. · all time
Since the insiders bought
- -97.7%Entry US$237,825.00 · Close at T+365 US$5,460.00
- -98.5%Entry US$1,764,000.00 · Close at T+365 US$26,197.50
- -98.5%Entry US$1,764,000.00 · Close at T+365 US$26,197.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.87
Analyst consensus
Income statement
RevenueUS$11.5M
Gross profitUS$7.7M67% margin
EBITDA-US$51.7M-449% margin
Net income-US$53.4M-130.9% margin
Valuation
P/Book0.1x
Beta-0.11
Balance sheet & cash
Market capUS$5.6M
Total debtUS$43.6M
Free Cash Flow-US$23.7M
Debt / Equity253%
Profitability & ownership
ROE-548.8%
ROA-38.0%
% insiders4.4%
% institutions1.8%
Last declaration on 12 March 2026
Declarations77 total
7,377 shares0Common StockSEC:0001193125-26-103914:0
11,740 shares0Common StockSEC:0001193125-26-018042:0
28,592 shares0Common StockSEC:0001193125-26-018040:0
11,740 shares0Common StockSEC:0001193125-26-018044:0
6,363 shares0Common StockSEC:0001193125-25-319518:0
7,377 shares0Common StockSEC:0001193125-25-319513:0
5,870 shares0Common StockSEC:0001193125-25-319508:0
11,740 shares0Common StockSEC:0001193125-25-319495:0
11,740 shares0Common StockSEC:0001193125-25-319528:0
2 sharesCommon StockSEC:0000950170-25-075332:0
1 sharesCommon StockSEC:0000950170-25-075339:0
4,922 shares0Common StockSEC:0000950170-24-114193:0
4,922 shares0Common StockSEC:0000950170-24-114192:0
16,503 shares0Common StockSEC:0000950170-24-114187:0
4,280 shares0Common StockSEC:0000950170-24-114194:0
4,922 shares0Common StockSEC:0000950170-24-114181:0
871 sharesCommon StockSEC:0001104659-24-063903:0
871 sharesCommon StockSEC:0001104659-24-063901:0
612 sharesCommon StockSEC:0001104659-24-063895:0
2,695 sharesCommon StockSEC:0001104659-24-063892:0
431 sharesCommon StockSEC:0001104659-24-063897:0
600 sharesCommon StockSEC:0001104659-24-048338:0
134 sharesCommon StockSEC:0001104659-24-048347:0
89 sharesCommon StockSEC:0001104659-24-048345:0
60 sharesCommon StockSEC:0001104659-24-048343:0
25 of 77 declarations
About Jaguar Health, Inc.
Jaguar Health, Inc. (NASDAQ: JAGX) is a United States-based specialty pharmaceutical company listed on the NASDAQ market and headquartered in San Francisco, California, United States. The company was founded on June 6, 2013, originally as Jaguar Animal Health, Inc., with a mission to develop and commercialize prescription and non-prescription products for companion animals and livestock. After its merger with Napo Pharmaceuticals in 2017, the business was renamed Jaguar Health, Inc. and gradually shifted its strategic focus toward human health, while retaining an animal-health legacy in its broader corporate history.
Today, Jaguar Health is best described as a commercial-stage and development-stage pharmaceutical company focused on gastrointestinal disorders. Its lead asset is crofelemer, a plant-derived compound extracted from the red latex sap of Croton lechleri, an Amazonian tree. Crofelemer underpins the company’s human-health strategy and is central to its rare-disease intestinal failure pipeline. Jaguar also markets or has marketed prescription products including Mytesi, Gelclair and Canalevia-CA1, alongside non-prescription animal-health products such as Neonorm. This portfolio gives the company a differentiated profile in biopharma, combining natural-product sourcing, GI-focused therapeutics and both human and animal health applications.
Read moreShow less
From a competitive standpoint, Jaguar Health occupies a small-cap niche position with a relatively concentrated revenue base and a heavy reliance on a limited number of products and clinical programs. That creates meaningful upside optionality if regulatory, clinical or partnership milestones are achieved, but it also leaves the company exposed to the execution and financing risks common to micro-cap biotechnology and specialty pharma names. The company emphasizes sustainable sourcing and fair-trade practices for crofelemer supply, which supports its brand positioning in plant-based medicine.
Geographically, Jaguar’s operating base is primarily the United States, with its principal executive offices in San Francisco and its equity trading on NASDAQ under JAGX. Recent developments have been notable. In January 2026, Jaguar signed a U.S. license agreement with Future Pak covering Mytesi and Canalevia-CA1, providing non-dilutive capital and allowing management to concentrate resources on late-stage crofelemer development for rare intestinal failure indications. In March 2026, the company announced a balance-sheet restructuring that reduced royalty and debt obligations. Jaguar also faced Nasdaq compliance issues during 2026, underscoring the company’s still-fragile market profile and the importance of ongoing capital, clinical and listing-rule execution.
